Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. - Test2 - elhamkhani - TriplyDB

Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure.

Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure.

http://www.wikidata.org/entity/Q46471367

about

Phosphate control in end-stage renal disease: barriers and opportunities Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients Phosphate control in dialysis N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.Intestinal npt2b plays a major role in phosphate absorption and homeostasis.Diabetes mellitus: channeling care through cellular discovery Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases Effect of niacin on FGF23 concentration in chronic kidney disease.Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium Novel avenues of drug discovery and biomarkers for diabetes mellitus.Intestinal phosphate transport.Water-soluble vitamins in people with low glomerular filtration rate or on dialysis: a review Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis Npt2b deletion attenuates hyperphosphatemia associated with CKD.Cell Life versus cell longevity: the mysteries surrounding the NAD+ precursor nicotinamide.Novel directions for diabetes mellitus drug discovery Phosphate binders: new products and challenges.Continuing exposure to low-dose nonylphenol aggravates adenine-induced chronic renal dysfunction and role of rosuvastatin therapy.The safety of phosphate binders.Hypophosphatemic effect of niacin extended release in ischemic kidney disease.Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients "Sly as a FOXO": new paths with Forkhead signaling in the brain Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease.Gastrointestinal phosphate handling in CKD and its association with cardiovascular disease.Use of nicotinamide to treat hyperphosphatemia in dialysis patients.Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality.The vitamin nicotinamide: translating nutrition into clinical care.Phosphate homeostasis and the renal-gastrointestinal axis.Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.Intestinal phosphate transport: a therapeutic target in chronic kidney disease and beyond?Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease?Advances in pharmacotherapy for secondary hyperparathyroidism.Regulation of renal phosphate handling: inter-organ communication in health and disease.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Nicotinamide and phosphate homeostasis in chronic kidney disease.

P2860

Q26853372-89F37F46-0069-47E1-97F9-93824553B653 Q27006968-CE980D50-D337-4D60-A030-9D484BF40098 Q27025339-19880223-6806-4B35-9AF5-9BCC9B4CD693 Q28069862-9C07AB8D-507F-48AE-8716-30D8D9ECB567 Q33410839-B617D1C3-B879-4AA4-840B-1C9A3866BD64 Q33432308-5328BB0A-C48A-4E9A-BC86-2AA83A261EA7 Q33561684-ADE83F74-E298-4DF4-97C9-CD83C1D178BF Q33749358-A8FBE2B3-250D-485C-B4F4-8F85D9F08D87 Q33770086-EE46C022-6D19-46E6-8383-463A524172D9 Q33899993-BD9A575D-E283-4BC5-A300-08E1568A3A83 Q33914268-9D2C7523-85E8-4350-AEB9-863994E03536 Q34147642-952106DA-1CFB-4153-9662-5C06477D7047 Q34552287-8BB053D3-A2D0-49C1-84D6-6D791F74952C Q34768129-BB78D5B2-ACBC-446F-B811-366B25F5317C Q34852823-F88A3CFE-C074-4F1F-B607-25B6D7EC66DC Q35351243-C06C5CDF-0CD2-4D02-888F-03259B200301 Q36280326-579784EA-D7E7-474D-9D79-D0AF6677B75F Q36447198-7AAD4F3E-82A9-4C03-91D0-05CDED5E232A Q36487424-A59B8324-FBE9-422D-A591-E34CF6F08C82 Q36522027-C2DC5790-C0BE-497F-A625-59BCBDDB662D Q36527133-3F39D4EA-D399-4EC9-843C-039DFC82B98A Q36565049-A2A6271A-9210-4E97-8DF4-1595D84D07B7 Q36606586-787F1EB2-2691-46D5-BEFC-EB818772314C Q36727444-4354C9FB-9EEC-4595-A6CB-C8D94CAC23CE Q36736674-849204AC-B667-4F35-A7E1-29533F4F8625 Q36944469-5A7EF075-99EB-40B0-9171-A3F29550196A Q37135110-3B7261D2-363D-457A-A8BD-0BAA9EB1C58A Q37188744-E5C84508-8FB0-4418-94B0-6820A0E7E10C Q37199788-B99C2336-990C-4E27-B45F-3E2867D4E7CC Q37288856-7000771F-12E3-49FC-94F4-612D918876E5 Q37374047-AF29E146-4A7A-4ECF-8919-5B3B9D0BE7AB Q37763810-E0B01D1C-1ADE-48A5-ABEF-37D234CE63A3 Q38049170-55E63D4A-9B72-4C44-B06B-4293FE023E12 Q38092792-CCA50B57-C513-4531-A67A-A4BEBAE3BD63 Q38185277-581537A4-0141-40AC-A959-2836DE7656B4 Q38223280-14CC6E99-DB08-41A8-A270-C5603F62FE82 Q38544533-6DB874EF-F869-46D9-BFC2-6AA1459B91C6 Q38571301-CC19F28A-7FE7-4227-8305-364DDB0A5500 Q38828902-8C6B40FD-BE1D-4998-B418-BD81B471E5F4 Q38842982-18A0F202-2C82-42AA-9403-62F2B2BA254B

P2860

Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure.

http://www.wikidata.org/entity/Q46471367

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Nicotinamide prevents the deve ...... adenine-induced renal failure.

@en

Nicotinamide prevents the deve ...... adenine-induced renal failure.

@nl

type

label

Nicotinamide prevents the deve ...... adenine-induced renal failure.

@en

Nicotinamide prevents the deve ...... adenine-induced renal failure.

@nl

prefLabel

Nicotinamide prevents the deve ...... adenine-induced renal failure.

@en

Nicotinamide prevents the deve ...... adenine-induced renal failure.

@nl

P1433

Q46471367-5C2C0FD0-AC60-4D84-B323-4B45EAF810A9

P1476

Q46471367-ED3E377A-4B91-40EF-9ED1-383AD53A15BE

P2093

Q46471367-37A25981-B40A-433F-9D1A-F33D64A2BE0D

Q46471367-5498E085-748E-426C-BFF4-11F31E829BD6

Q46471367-5D57C1CC-75F4-41A4-92B8-25A00D2C2743

Q46471367-B504BC50-9924-4135-BF9A-1C54F87C9AB4

P2860

Q46471367-10B6A3E5-84E9-4DDB-8482-5F2071DD5BEE

Q46471367-10C04365-995A-4B82-A60B-6FC4E3F86E78

Q46471367-20EF1504-416C-4848-947F-00C301C19BDE

Q46471367-2E939AC6-81C6-4905-8A18-BA48DF20E940

Q46471367-556DCA0E-3C8D-4FC0-A8A3-1FE2B0B35A2B

Q46471367-7E7617F4-2C02-4249-886C-1FCD9AE91232

Q46471367-DF9EBADA-0BB2-48E9-A819-F3512247D0FE

Q46471367-ECC5305A-5C51-462F-9F8B-0CD97B41F11F

Q46471367-ED5FF712-8362-44B7-9938-7D845DAAC243

Q46471367-EE3771A6-AC68-4C46-AF0B-8390AA079F24

P304

Q46471367-96AFCC82-0CEA-48FA-A224-745C36CC1E9A

P31

Q46471367-686B1923-AEEE-4B7A-8F10-5433FC626E7D

P356

Q46471367-F4640CD9-FD84-448F-B1B2-0CA666389C72

P407

Q46471367-7BD54CD2-2515-40BC-92FF-DAA8636278DA

P433

Q46471367-92613167-4450-44D0-8879-1BC1AE173CE1

P478

Q46471367-7A2E2B99-00B8-4676-808E-0C3733438F46

P577

Q46471367-634E3201-BFF5-4317-ACFB-DC7C299EE4B4

P5875

Q46471367-FA1258F0-4AFE-412E-B073-02D23AD35078

P698

Q46471367-56B555B6-3AE1-4A69-9228-7E58B59910B4

P356

P1433

Nephrology Dialysis Transplantation

P1476

Nicotinamide prevents the deve ...... adenine-induced renal failure.

@en

P2093

Hiroaki Ohno

http://www.w3.org/2001/XMLSchema#string

Nobuaki Eto

http://www.w3.org/2001/XMLSchema#string

Takeyoshi Yamashita

http://www.w3.org/2001/XMLSchema#string

Yoko Miyata

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine

Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine

Parallel adaptation of the rabbit renal cortical sodium/proton antiporter and sodium/bicarbonate cotransporter in metabolic acidosis and alkalosis.

Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat

Role of dietary factors in the progression of chronic renal disease.

Age-dependent regulation of rat intestinal type IIb sodium-phosphate cotransporter by 1,25-(OH)(2) vitamin D(3).

Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease.

Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine.

P304

1378-1384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFH781

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7868630

http://www.w3.org/2001/XMLSchema#string

P698

15870221

http://www.w3.org/2001/XMLSchema#string